Richard Pomerantz, MD
Pulmonary Disease · Hickory, NCNPI 1154321321
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,282 and has fallen 78.8% since, to $272 in 2025.
Across 81 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$242
- GSK$203
- AstraZeneca$201
- Actelion Pharmaceuticals US, Inc.$180
- Regeneron Healthcare Solutions, Inc.$157
- ANI Pharmaceuticals, Inc.$130
- plus $782 from 20 others
What the payments were for
- Food & beverage$1,87999%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 8 | $242 |
| GSK | 12 | $203 |
| AstraZeneca | 5 | $201 |
| Actelion Pharmaceuticals US, Inc. | 5 | $180 |
| Regeneron Healthcare Solutions, Inc. | 4 | $157 |
| ANI Pharmaceuticals, Inc. | 6 | $130 |
| Grifols USA, LLC | 7 | $119 |
| Mylan Specialty L.p. | 4 | $76 |
| Amgen | 4 | $69 |
| Boehringer Ingelheim | 4 | $69 |
| Harmony Biosciences LLC | 3 | $60 |
| Insmed, Inc. | 3 | $59 |
| Sanofi | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Novartis | 2 | $35 |
| Gilead | 1 | $29 |
| Verona Pharma, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Inogen, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| AbbVie | 1 | $19 |
| Baxter Healthcare | 1 | $19 |
| Electromed, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| CSL Behring | 1 | $15 |
| Pulmonx Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,894 in reported general payments places this provider in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 21 | $283,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 145 | $115,167 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 130 | $84,010 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 98 | $65,780 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 62 | $36,714 |
| EliquisApixaban | 47 | $35,091 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $29,458 |
| Spiriva RespimatTiotropium Bromide | 34 | $22,772 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 19 | $13,893 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $7,202 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 207 | $6,345 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $3,988 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $3,570 |
| Ventolin HfaAlbuterol Sulfate | 37 | $2,413 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $69 | $372,148153 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $203 | $181,339256 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $201 | $105,106165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Hickory
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
- Priyank DesaiRocky Mount$199K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.